Published in Vaccine Weekly, June 9th, 2004
This approach combines the RNA-based gene inhibition technology of SomaGenics with the immunomodulatory and vaccine technology under development by Juvaris BioTherapeutics. The effort is directed towards the development of novel methods for immediate inhibition of pathogenesis, stimulation of innate immunity, and the development of specific immunity to disease-related antigens.
The initial focus of this collaboration is a novel immune stimulant and specific...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly